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Background: Leptin, an adipocytokine produced mainly by white adipose tissue, has a broad role in the regulation
of neuronal functions. Accumulating evidence has revealed that leptin plays an important role in influencing
neuropathic pain, shown recently by the finding that chronic administration of leptin induced thermal hyperalgesia
and mechanical allodynia in naïve rats. Chronic constriction sciatic nerve injury (CCI) is a well characterized model
used for studying neuropathic pain. The present study was designed to investigate whether leptin plays a role in
neuropathic pain in rats induced by CCI by examining particular pain behaviors.
Results: After sciatic nerve injury in rats, endogenous levels of leptin and leptin receptor (OB-Rb) were increased
in a time dependent manner within the ipsilateral dorsal root ganglion (DRG). Intrathecal administration of
leptin once daily for 6 days, beginning 7 days after CCI, alleviated neuropathic pain and decreased the
expression of IL-6, TNFα, and the P2X2 and P2X3 receptors. Attenuation of endogenous OB-Rb in the DRG by
intrathecal administration of OB-Rb antisense oligonucleotides did not change thermal hyperalgesia or
mechanical allodynia induced by CCI.
Conclusions: Our findings suggest that exogenous leptin can alleviate the chronic neuropathic pain caused by
CCI. The leptin effect may be mediated by attenuated expression of IL-6, TNFα, and the P2X2 and P2X3 receptors
in the DRG of CCI rats.
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Neuropathic pain is a severe health problem for which
there is a lack of effective therapy [1]. It is caused by an
injury to the peripheral or central nervous system.
Characteristic features of neuropathic pain are hyper-
algesia allodynia and spontaneous pain [2]. Numerous
neuroanatomical, neurophysiological, and neurochemical
mechanisms are thought to contribute to the development
and maintenance of neuropathic pain [3]. However, neuro-
pathic pain remains a prevalent and persistent clinical* Correspondence: liangsd@hotmail.com; jxchp2000@126.com
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reproduction in any medium, provided the orchallenge as its pathogenesis is unknown. Consequently,
there is a considerable need to explore novel treatment
modalities for neuropathic pain management.
The dorsal root ganglion (DRG) is an anatomically
discrete structure that forms part of the peripheral nervous
system (PNS), and is located laterally to neural tube. It
contains pseudounipolar neurons that convey sensory
information from the periphery to the central nervous
system (CNS). The DRG is recognized as one of the organs
that may be damaged in peripheral sensory neuropathic
pain states [4]. Furthermore, It has been well established
that nerve lesions induce changes in gene and protein
expression within the DRG which correspond to induced
neuropathic pain [5,6].
Leptin, the product of the obese (ob) gene, is a 16-kDa
polypeptide hormone that was first associated with obesityhis is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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interest in leptin was concerned with its effects on fat
mobilization and energy homeostasis. However more
recently, numerous additional roles have been identified,
Thus it has been shown that leptin plays a vital role in the
regulation of numerous and varied biochemical pathways
throughout the body, such as in metabolism, immune and
reproductive function, bone homeostasis, insulin sensitivity
and neuronal protection. The actions of leptin are mediated
by leptin receptors that are widely distributed across many
tissues including the spleen, testes, kidney, liver, lung,
adrenal, pituitary, hypothalamus and brain. In addition,
our previous research found that leptin receptors are
expressed in DRG neurons [8].
A variety of studies have shown that leptin plays a pivotal
role in neuronal survival and neuroprotection [9,10],
and importantly, that acute leptin treatment enhances
functional recovery after spinal cord injury [11]. Recent
reports also provide a link between leptin and chronic
neuropathic pain. Intrathecal leptin administration for
7 days induced thermal hyperalgesia and mechanical
allodynia in naïve rats similar to that seen in CCI rats
[12]. Leptin-deficient animals, (ob/ob mice), showed an
absence of tactile allodynia induced by partial sciatic
nerve ligation (PSL). However, daily perineural injection
of leptin into the ligatured SCN during the early phases of
PSL reversed the failure of ob/ob mice to develop tactile
allodynia. By contrast, treatment of ob/ob mice with leptin
during late phases of PSL did not affect the failure of these
mutant mice to develop PSL-induced tactile allodynia
[13]. However, under neuropathic pain conditions, the
role of leptin is still unknown. In this report we explore
the possibility that intrathecal exogenous leptin can
alleviate neuropathic pain in a rat model of CCI. We
subsequently investigate whether the leptin effect on
neuropathic pain we identify is mediated by pain relevant
mediators including the P2X2 and P2X3 receptors.
Results
Leptin and OB-Rb are up-regulated in L4-6 DRG of
CCI rats
It has been reported that leptin and leptin receptor (OB-Rb)
levels increased in the spinal cord after CCI [12]. However,
the expression pattern of leptin and OB-Rb in the ipsilateral
DRG of CCI rats is still unknown. In the present study,
the time course of the expression of leptin and OB-Rb
in the DRG in response to CCI was analysed using
semi-quantitative RT-PCR and Western Blot analysis.
Leptin and OB-Rb levels were measured at 1, 7, 14 and
21 days after CCI and in the sham group (Figure 1). The
results show that both leptin mRNA and protein levels
significantly increased 14 and 7 days after CCI respectively,
as compared to the sham group. Maybe CCI lead to a
response including improved leptin mRNA translation,thus causing leptin protein levels to increase prior to the
detected mRNA upregulation. In addition, we found that
OB-Rb mRNA and protein levels significantly increased 7
and 14 days after CCI respectively, as compared to the
sham group. At day 21 after CCI, leptin and OB-Rb were
still maintained at high levels (Figure 1).
Intrathecal leptin administration alleviated the
neuropathic pain of CCI rats
It has been shown that chronic administration of leptin
induced thermal hyperalgesia and mechanical allodynia
in the naïve rat model [12]. However, any effect of leptin
on thermal hyperalgesia and mechanical allodynia induced
by CCI is unknown. In this study, leptin was intrathecally
delivered once daily for 6 days beginning 7 days after CCI.
The thermal withdrawl latency (TWL) and withdrawal
threshold (MWT) were measured to evaluate the effects
of leptin on pain thresholds in CCI rats. At day 7 after
CCI, a time when neuropathic pain is known to be well
established, leptin was intrathecally administered once
daily for 6 days. The TWL and MWT were measured
2 h after each treatment. As shown in Figure 2, intra-
thecal treatment with leptin (10 μg/kg) for 4 and 5 days
dramatically increased TWL and MWT as compared to
vehicle-treated CCI rats. Intrathecal treatment with leptin
(50 μg/kg) for 2 and 3 days significantly increased TWL
and MWT as compared to vehicle-treated CCI rats.
Intrathecal treatment with leptin (200 μg/kg) for 2 days
significantly increased both TWL and MWT as compared
to the vehicle-treated CCI rats.
Intrathecal leptin administration attenuated the
expression of IL-6, TNFα, and the P2X2 and P2X3
receptors in L4-6 DRG of CCI rats
To determine the functional role of the leptin effect on
neuropathic pain at a molecular level, we examined
whether leptin would modulate the expression of IL-6,
TNFα, and the P2X2 and P2X3 receptors. It has previ-
ously been shown that IL-6 protein and mRNA levels
increased in both lumbar (L4-5) and cervical (C7-8)
dorsal root ganglia (DRG) following CCI [14], and that
IL-6 contributes to the development of neuropathic
pain following motor fiber injury [15]. Our previous
studies have shown that P2X2/3 receptors participate in
the regulation of neuropathic pain [16]. In the present
work, we report that IL-6, TNFα, and the P2X2 and
P2X3 receptors were increased in the DRG of CCI rat
(Figure 3). Furthermore, intrathecal administration of
leptin (50 μg/kg and 200 μg/kg) efficiently attenuated
the expression of IL-6, TNFα, and the P2X2 and P2X3
receptors (Figure 3). These data indicate that leptin
may alleviate the pain behaviors by inhibiting IL-6,
TNFα, and the P2X2 and P2X3 receptors in the DRG of
CCI rats.
Figure 1 Leptin and OB-Rb were upregulated in a time dependent manner in L4-6 DRG of CCI rats. (A) The expression of leptin mRNA
and OB-Rb mRNA was increased in the DRG of CCI rats. Leptin and OB-Rb mRNAs were detected by RT-PCR at days 1, 7, 14 and 21 after CCI.
(B) Leptin and OB-Rb protein were increased in the DRG of CCI rats. Leptin and OB-Rb protein were detected by Western Blot analysis at days of
1,7,14 and 21 after CCI. Data are shown as mean ± S.E.M, n = 6. *P < 0.05, #P < 0.01 and @P < 0.001 vs sham group.
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immunoreactivity of P2X2 and P2X3 receptors
in L4-6 DRG of CCI rats
Glia and neurons in the DRG can be clearly distinguished
under the light microscope. Immunohistochemical staining
using antibodies directed against P2X2 and P2X3 demon-
strated both these receptors werepresent in the cytoplasm
of DRG neurons. A semi-quantitative approach was taken
to evaluate receptor levels using optical density to generate
“stain values” for each group that were subsequently com-
pared. These results indicated that P2X2 and P2X3 receptor
expression increased in DRG neurons of CCI rat at the
protein level; furthermore, intrathecal leptin administration
(50 μg/kg and 200 μg/kg) significantly attenuated expression
of P2X2 and P2X3 receptors (Figure 4).
Effects of intrathecal OB-Rb antisense oligonucleotides
on the pain behaviors induced in CCI rats
It has been reported that deletion of the leptin receptor
in mice prevented neuropathic pain development [17].
However, the role the leptin receptor signal plays inFigure 2 Leptin alleviates the neuropathic pain. The thermal withdrawl
measured after intrathecal administration of leptin. Leptin was intrathecally de
arrows. The TWL and MWT were tested 2 h after each administration of leptin
vs CCI + Vehicle group.neuropathic pain is still unknown. Therefore, we evaluated
whether there was any change in the pain behaviors TWL
and WMT in CCI rats following intrathecal adminis-
tration of OB-Rb antisense oligonucleotides. We found
that OB-Rb antisense oligonucleotides (120 μg/kg and
240 μg/kg) significantly attenuated the expression of
OB-Rb (Figure 5). However, OB-Rb antisense oligonucleo-
tides (240 μg/kg) could not change the pain behaviors
induced in the CCI model (Figure 6).
Discussion
The present study demonstrated the following novel
findings: (1) leptin and OB-Rb are expressed within the
ipsilateral DRG and are up-regulated after CCI in a time-
dependent manner. (2) Exogenous leptin administration
alleviated the chronic neuropathic pain of rat caused by
CCI. (3) Exogenous leptin administration attenuated the
expression of IL-6, TNFα, and the P2X2 and P2X3 in rat
DRG induced by CCI. (4) Attenuation of endogenous OB-
Rb expression in the DRG by intrathecal OB-Rb antisense
oligonucleotides did not change the thermal hyperalgesialatency TWL (A) and mechanical withdrawl threshold MWT (B) were
livered once daily for 6 days beginning 7 days after CCI, as indicated by
. Data are shown as mean ± S.E.M, n = 5. *P< 0.05, #P< 0.01 and @P< 0.001
Figure 3 Leptin attenuates the expression of IL-6, TNFα, and the P2X2 and P2X3 receptors in L4-6 DRG of CCI rats. (A) Leptin decreased
the expression of P2X2, P2X3 receptors, IL-6 and TNFα mRNAs in a dose dependant manner. Leptin was intrathecally delivered once daily for
6 days beginning 7 days after CCI. The rats were sacrificed 24 h after the last leptin administration. The expression of P2X2 and P2X3 receptors
mRNAs, and IL-6 and TNFα mRNAs were detected using RT-PCR. (B) Leptin decreased the expression of P2X2, P2X3, IL-6 and TNFα protein in a
dose dependant manner. Leptin was delivered intrathecally once daily for 6 days beginning 7 days after CCI. The rats were sacrificed 24 hour after
the last leptin administration. The expression of P2X2, P2X3, IL-6 and TNFα protein was detected by Western Blot. Data are shown as mean ± S.E.
M, n = 6. *P < 0.05, #P < 0.01 and @P < 0.001 vs CCI + Vehicle group.
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reveal a critical role of leptin in neuropathic pain and a
functional link between leptin and P2X2/3 receptors, IL-6
and TNFα. These findings suggest a different role for
leptin in CCI rats compared to naïve rats.
Leptin is known to influence brain development. Leptin
deficient ob/ob mice have smaller brains [18] and leptin
administration increased brain weight in ob/ob mice [19].
It has also been shown that leptin can play a neuropro-
tective role after neuronal injury. Leptin protects against
delayed ischemic neuronal death in hippocampal CA1
neurons by maintaining the pro-survival states of the
Akt and ERK1/2 MAPK signaling pathways, thereby
preventing apoptotic neuronal loss [20]. Leptin has a
prominent neuroprotective and anti-inflammatory role
following spinal cord damage and together these studies
highlight leptin as a promising therapeutic agent [11].
Administration of leptin to transgenic mouse models of
AD (Alzheimers disease) reduces neuronal pathology and
improves cognitive performance [21].
Recent studies have shown leptin plays an important
role in neuropathic pain induced by nerve injury. Chronic
administration of leptin induced thermal hyperalgesia and
mechanical allodynia in naïve rats [12] and its mechanism
involved an enhancement of N-methyl-D-aspartate (NMDA)
induced spinal excitation [22]. Interestingly, leptin admin-
istration afforded significant neuroprotection of mouse
cortical neurons against NMDA cytotoxicity [23]. These
results suggest that leptin contributed towards neuro-
pathic pain through evoking NMDA signaling in naïve
rats but alternatively, performed a neuroprotective roleby inhibiting NMDA cytotoxicity under conditions of
nerve injury. Thus, we evaluated the role(s) of leptin on
neuropathic pain induced by CCI in rats. Our results show
that exogenous leptin administration alleviated the pain
behaviors induced by CCI. The mechanism of this action
may be relevant to the neuroprotective role of leptin
under conditions of nerve injury. However, decreasing the
OB-Rb levels in the DRG of CCI rat did not change the
TWL and MWT pain behaviors.
Adenosine, 5′-triphosphate (ATP) is a ubiquitous mol-
ecule found in every cell in the millimolar concentration
range, and is released into the extracellular matrix after
tissue injury. ATP release from different cell types is impli-
cated in the initiation of pain by activating P2 receptors
on sensory nerve terminals [24]. Known P2X subtypes
with a role in nociception include P2X3 and P2X2/3 recep-
tors, which are considered potential therapeutic targets for
the management of pathological conditions. Suppressing
the expression of P2X3 receptors in the DRG, attenuated
hyperalgesia following CCI in rats [25]. Activation of
the P2X3 receptors produced fast desensitizing currents
in DRG neurons, and in contrast, P2X3 mouse mutants
showed either a lack of fast desensitizing currents in-
duced by ATP or a significant reduction in pain behav-
iors in response to ATP [26,27]. Our previous results
similarly showed that inhibiting the P2X2/3 receptors
of primary sensory neurons alleviated chronic neuro-
pathic pain [28]. In this study, we found that leptin
could alleviate the pain behaviors induced by CCI and
decreased the expression of P2X2/3 receptors. These results
suggest that the effect of leptin on neuropathic pain is
Figure 5 Intrathecal administration of OB-Rb antisense oligonucleotides decreased OB-Rb mRNA and protein expression. (A) Intrathecal
OB-Rb antisense oligonucleotides (120 μg/kg and 240 μg/kg) significantly decreased the expression of OB-Rb mRNA. (B) Intrathecal OB-Rb antisense
oligonucleotides (120 μg/kg and 240 μg/kg) significantly decreased the expression of OB-Rb protein. The drugs were delivered intrathecally once daily
for 6 days beginning on day 7 after CCI. The rats were sacrificed 24 h after of the last leptin administration. Data are shown as mean ± S.E.M, n = 6.
*P < 0.05, and #P < 0.01 vs CCI + Vehicle group.
Figure 4 Leptin administration decreases the immunoreactivities of P2X2 and P2X3 receptors in L4-6 DRG of CCI rats. Leptin
administration decreased the immunoreactivity of P2X2 (A) and P2X3 (B) receptors within the DRG of CCI rats. P2X2 and P2X3 receptors
immunoreactivity (brown) was detected in DRG neurons of sham, CCI + vehicle, CCI + Leptin (10 μg), CCI + Leptin (50 μg) and CCI + Leptin
(200 μg) treatments. Leptin was intrathecally delivered once daily for 6 days beginning 7 days after CCI. The rats were sacrificed 24 h after the last
leptin administration. Arrows indicate P2X2 and P2X3 receptor positive neurons. Scale bar is 20 μm. Data are shown as mean ± S.E.M, n = 5.
*P < 0.05, and #P < 0.01 vs CCI + Vehicle group.
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Figure 6 Effects of intrathecal OB-Rb antisense oligonucleotides on the pain behavior induced in CCI rats. The thermal withdrawl latency
TWL (A) and mechanical withdrawl threshold MWT (B) were measured after intrathecal administration of antisense nucleotides directed against
the leptin receptor. The AS oligonucleotides were delivered intrathecally once daily for 6 days beginning on day 7 after CCI, as indicated by arrows.
The TWL and MWT were tested 2 h after each administration of leptin. Data are shown as mean ± S.E.M, n = 6.
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receptors.
Neuropathic pain often develops following peripheral
nerve damage. In such pathological conditions, proinflam-
matory cytokines and chemokines are upregulated in the
DRG associated with the injured nerves [29]. Increasing
IL-6 levels in afferent neurons in the DRG and spinal cord
contributes to the development of neuropathic pain follow-
ing motor fiber injury [15]. IL-6 protein was significantly
elevated in DRG of CCI rats in a time dependant manner
[30]. Interestingly, the IL-6 signal is also involved in
the maintenance of experimentally induced mechanical
hypersensitivity [31]. Several lines of evidence indicate
that TNFα also plays a key role in neuropathic pain. In
response to either peripheral nerve injury or after spinal
cord injury, TNFα levels are increased in the spinal cord
[32,33]. In the CCI model of peripheral neuropathic pain,
neutralizing antibodies directed against TNFα reduce
thermal hyperalgesia and mechanical allodynia [34]. In this
study, we found that administration of leptin decreases the
expression of IL-6 and TNFα. These results imply that the
effect of leptin on alleviating neuropathic pain is partly
mediated by inhibiting the expression of IL-6 and TNFα.
The actions of leptin are mediated by its receptor OB-Rb.
OB-Rb exists in a number of different isoforms which are
distinguished by the length of their intracellular domains as
the long isoform (OB-Rb) and short isoforms (OB-Rs).
The OB-Rb isoform is believed to be the functional
signal-transducer in the hypothalamus, while the remaining
OB-Rs are thought to serve as leptin transporters or to
mediate leptin degradation [35]. Mice with the leptin
receptor null mutation (db/db) demonstrate a decreased
sensitivity to mechanical stimulation and a decreased
nociceptive response in the affected hind paw during
the second phase of a formalin test [17]. In the current
study, our results show that attenuation of endogenous
OB-Rb expression by intrathecal OB-Rb antisense oligo-
nucleotides did not change thermal hyperalgesia or mech-
anical allodynia induced by CCI. Together these findingssuggest that blocking the leptin receptor prevents neuro-
pathic pain development. However, during the CCI pain
condition, attenuation of OB-Rb expression did not change
the TWL and MWT, easily identifiable pain behaviors.
Therefore, the mechanism underlying alleviation of neuro-
pathic pain by leptin is unknown and needs to be further
investigated in order to provide options for the treatment
of pain.
Conclusions
In conclusion, our study demonstrates that leptin and
OB-Rb were increased within the DRG after sciatic nerve
injury. Intrathecal leptin alleviated neuropathic pain and
decreased the expression of P2X2 and P2X3 receptors,
IL-6 and TNFα. Attenuation of the OB-Rb in the DRG
of CCI rats did not change the pain behaviors. These data
illustrate that leptin can alleviate chronic neuropathic
pain, and this role of leptin may be mediated by P2X2 and
P2X3 receptors, IL-6 and TNFα.
Materials and methods
Animals
Male Sprague-Dawley rats weighing 220-250 g were
provided by the Center of Laboratory Animal Science
of Nanchang University. The rats were fed a standard
laboratory diet under controlled temperature and 12-h
light/dark cycle at 20-22°C. All experimental procedures
were approved by the Institutional Animal Care and Use
Committee of the Medical College of Nanchang University.
All efforts were undertaken to minimize the number of
animals used and their discomfort.
Experimental design
Four series of experiments were performed in this study.
In the first experiment, to analyze the time course of ex-
pression of leptin and OB-Rb in rat DRG after CCI, rats
were randomly divided into 5 groups with 6 rats in each
group: a sham group (Sham), a postoperative day 1 group
(D1), a postoperative day 7 group (D7), a postoperative day
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Expression levels of leptin and OB-Rb in L4-6 DRG were
analysed at days 1, 7, 14 and 21 after CCI for the experi-
mental groups D1, D7, D14 and D21 described above. For
the sham group, operations were performed and DRGs
harvested and analysed for OB-Rb and leptin on day 7.
In the second experiment, to evaluate the role of leptin
on neuropathic pain, and P2X2 and P2X3 receptors, IL-6
and TNFα expression, rats were randomly divided into 5
groups with 8 rats in each group: a sham group (sham),
a vehicle group (Vehicle), and three experimental groups
with leptin administration at 10 μg/kg (leptin 10 μg), at
50 μg/kg (leptin 50 μg) and 200 μg/kg (leptin 200 μg).
The drugs were delivered intrathecally once daily for
6 days, beginning on day 7 after CCI.
In the third experiment, to test the effects of inhibiting
OB-Rb expression using OB-Rb antisense oligonucleotides,
rats were randomly divided into 6 groups with 6 rats in
each group: a vehicle group (Vehicle), as well as two
control groups of rats with mismatch oligonucleotides
to OB-Rb at 60 μg/kg (MM-ODN 60 μg), and 120 μg/kg
(MM-ODN 120 μg). There were three experimental
groups with OB-Rb antisense oligonucleotides administered
at 60 μg/kg (AS-ODN 60 μg), 120 μg/kg (AS-ODN 120 μg)
or or240 μg/kg (AS-ODN 240 μg). The drugs were
delivered intrathecally once daily for 6 days beginning
on day 7 after CCI.
In the fourth experiment, to examine the role of OB-Rb
antisense oligonucleotides on pain behaviors induced by
CCI, the rats were randomly divided into 4 groups with 6
rats in each group: a sham group (sham), a vehicle group
(Vehicle), a group administered mismatch oligonucleotides
at 120 μg/kg (MM-ODN 120 μg) and a group administered
OB-Rb antisense oligonucleotides at 240 μg/kg (AS-ODN
240 μg). The drugs were delivered intrathecally once daily
for 6 days, beginning on day 7 after CCI.
The chronic constriction injury (CCI) model
The CCI model was established as previously described
[36]. Briefly, rats were anesthetized with sodium pento-
barbital (40 mg/kg, i.p.). The sciatic nerve was exposed
and loosely ligated with sterile 4-0 catgut thread at four
consecutive sites with an interval of approximately 1 mm.
Meanwhile, a sham surgery was performed with the sciatic
nerve exposed but not ligated. Animals were kept warm
and allowed to recover from anaesthesia.
Evaluation of the pain behavior
The testing procedure was performed according to previ-
ously published protocols [36]. The mechanical withdrawal
threshold (MWT) was determined to evaluate mechanical
hyperalgesia using calibrated von Frey filaments (BME-403,
Tianjing, China). Thermal hyperalgesia was measured using
a thermal paw stimulation system (BME-410C, Tianjin,China) and expressed as thermal withdrawal latency
(PWL), the time taken for thermal discomfort to be
noticed and elicit paw withdrawal. Each rat was measured
three times and the mean value was taken as the threshold
value.Reverse transcription-polymerase chain reaction (RT-PCR)
Total RNA was isolated using TRIzol (Invitrogen, Carlsbad,
CA, USA) according to the manufacturer’s protocol. 1000 ng
total RNA was used as a template for reverse transcription
using the Applied Biosystems Reverse Transcription Kit
(Applied Biosystems, Foster City, CA, USA). PCR amplifica-
tion of P2X2, P2X3 receptors and β-actin (control) was
carried out according to our previous method using
olignucleotides as described in [28]. Oligonucleotides
for amplification of leptin and OB-Rb were as follows:
for leptin, sense: 5′-CCTGGAAGCCTCGCTCTACT-3′,
and antisense: 5′-ATGGAATCGTGCGGATAACT-3′; for
OB-Rb, sense: 5′-CTGGGTTTGCGTATGGAAGT-3′, and
antisense: 5′-CCAGTCTCTTGCTCCTCACC-3′. The PCR
products were amplified using the following cycling pa-
rameters: 94°C for 5 min, followed by 35 cycles of 94°C for
45 s, 53°C for 30 s, and 72°C for 40 s, and finally a single
cycle at 72°C for 5 minutes.Western blot analysis
30 μg samples of total protein were separated using 6.5%
(for OB-Rb analysis) or 10% (for P2X2 and P2X3 receptors,
leptin and IL-6 analysis) SDS-polyacrylamide gel electro-
phoresis and transferred onto a polyvinylidene difluoride
membrane. After incubation with primary antibody against
either P2X2 or P2X3 receptors, IL-6, leptin or OB-Rb (Santa
Cruz Biotecnology, Santa Cruz, CA, USA), the membrane
was incubated with peroxidase conjugated secondary
antibodies (Cell Signaling Technology, Danvers, MA,
USA). Immunodetection was by using the Pierce-enhanced
chemiluminescence substrate (Thermo Scientific, Waltham,
MA, USA). β-actin antibody (Santa Cruz Biotecnology,
Santa Cruz, CA, USA) was used as a loading control.Immunohistochemistry
Six DRGs from 6 rats were analysed from each group.
Formalin-fixed, paraffin-embedded tissue was sectioned
at 5 μm, and every fifth section was used for immuno-
histochemistry (IHC), with at least 40 sections analysed
in each group. IHC was carried out as previously described
[23]. Primary antibody against P2X2 or P2X3 receptor
(Santa Cruz Biotecnology, Santa Cruz, CA, USA) was used.
Protein localization was detected following incubation
with diaminobenzidine (DAB) and H2O2 for 2 min. Finally,
sections were dehydrated in ethanol and mounted with
neutral balsam.
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Data reflect the mean ± S.E.M. Comparisons of means
between two groups was carried out using a t-test and
those between multiple groups with one way analysis of
variance (ANOVA). A value of P < 0.05 was considered
statistically significant.
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